Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 629 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Cómo solicitar Medicare cuando tiene cáncer December 12, 2023 FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection... April 19, 2024 Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs June 25, 2020 ESMO Welcomes Draft Report on Europe’s Beating Cancer Plan (BCP) Which... April 1, 2026 Load more HOT NEWS Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients... Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,...
